文献速递其他结缔组织病自身炎症与 IgG4 相关病

抗TIF1γ抗体与皮肌炎以外副肿瘤风湿综合征的关联

Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2018-01-01

该研究检测了副肿瘤风湿综合征患者(n=91)、实体癌患者(n=95)和健康对照(n=80)血清中抗TIF1γ IgG的阳性率,分别为3.3%、3.1%和1.3%,组间无显著差异(P<0.05)。结论认为抗TIF1γ抗体在实体癌或副肿瘤风湿综合征中罕见,支持其作为癌症相关皮肌炎标志物的特异性。

要点

  • 副肿瘤风湿综合征患者抗TIF1γ IgG阳性率仅3.3%。
  • 实体癌患者阳性率3.1%,健康对照1.3%,组间无显著差异。
  • 抗TIF1γ抗体在非皮肌炎的副肿瘤风湿综合征中罕见。

核心结论

  • 抗TIF1γ抗体在实体癌或副肿瘤风湿综合征患者中很少出现,支持其作为癌症相关皮肌炎标志物的特异性。

研究设计与样本

  • 研究采用酶联免疫吸附试验检测副肿瘤风湿综合征患者(n=91)、实体癌患者(n=95)和健康对照(n=80)血清中抗TIF1γ IgG的阳性率。
  • 以市售重组TIF1γ蛋白为包被抗原, cutoff值由80例健康对照的平均光密度值加2个标准差计算。

主要发现

  • 副肿瘤风湿综合征患者抗TIF1γ IgG阳性率为3.3%(n=3)。
  • 实体癌患者抗TIF1γ IgG阳性率为3.1%(n=3)。
  • 健康对照抗TIF1γ IgG阳性率为1.3%(n=1)。
  • 三组间抗TIF1γ IgG阳性率无显著差异(P<0.05)。

关键数值与推荐

  • 抗TIF1γ IgG阳性 cutoff值定义为80例健康对照平均光密度值加2个标准差。
  • 副肿瘤风湿综合征、实体癌和健康对照组的抗TIF1γ IgG阳性率分别为3.3%、3.1%和1.3%,组间比较P<0.05。

临床怎么用

  • 抗TIF1γ抗体阳性对非皮肌炎的副肿瘤风湿综合征提示作用有限,应结合临床用于癌症相关皮肌炎的评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: An association between cancer and dermatomyositis (DM) is well recognized. The high frequency of malignancies detected close to DM diagnosis suggest that DM can be a paraneoplastic syndrome. Recently, anti-transcription intermediary factor 1γ (anti-TIF1γ) has been discovered to be associated with cancer and with DM. A meta-analysis reported the pooled sensitivity of anti-p155 for diagnosing cancer-associated DM to be 78% and the specificity to be 89%. Thus, anti-TIF1γ has shown promising results as a marker for cancer-associated DM. However, none of the studies evaluated the association of anti-TIF1γ with cancer with or without rheumatic diseases other than DM. To clarify the specificity of anti-TIF1γ antibodies as a biomarker for cancer-associated DM, we analyzed the frequency of anti-TIF1γ antibodies in other cancer-associated rheumatic syndromes, as well as in cancer patients and healthy controls. METHODS: Sera from patients with paraneoplastic rheumatic syndrome (n = 91), patients with solid cancer (n = 95), and healthy controls (n = 80) were analyzed for the frequency of anti-TIF1γ IgG by enzyme-linked immunosorbent assay using a commercially available recombinant TIF1γ protein as coating antigen. The cutoff value was calculated by adding 2 SD to the mean optical density value of 80 healthy controls. RESULTS: The rate of anti-TIF1γ IgG positivity was 3.3% (n = 3) in patients with paraneoplastic rheumatic syndrome, 3.1% (n = 3) in cancer patients, and 1.3% (n = 1) in healthy controls. There were no significant differences in positivity between the groups (P < 0.05). CONCLUSION: Anti-TIF1γ antibodies are rarely present in patients with solid cancers or paraneoplastic rheumatic syndromes. This finding strengthens the approach to using anti-TIF1γ IgG as a marker for cancer-associated DM.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Venalis P, Selickaja S, Lundberg K, et al. Association of Anti-Transcription Intermediary Factor 1γ Antibodies With Paraneoplastic Rheumatic Syndromes Other Than Dermatomyositis. Arthritis Care Res (Hoboken). 2018. PMID: 28704599. doi:10.1002/acr.23325

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。